Press-release for stocks for biogen inc.

for entities : Biogen inc.

save search

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Published: 2024-03-31 (Crawled : 00:00) - prnewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -10.23% | O: -0.88% H: 0.0% C: 0.0%
leqembi fda disease license treatment alzheimer's application submission

Pilates Equipment Market size to grow by USD 101.05 million from 2022 to 2027, North America to account for 37% of the growth, Technavio
Published: 2024-03-19 (Crawled : 21:00) - prnewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -10.74% | O: -0.66% H: 1.0% C: 0.45%
america million market

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ABCL | $3.91 -0.26% 0.0% 540

| -15.09% | O: 5.03% H: 0.0% C: 0.0%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -12.58% | O: 0.03% H: 3.1% C: 3.03%
neurological

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -20.26% | O: -3.72% H: 0.58% C: -3.82%
skyclarys first approval treat therapy

Biogen to Realign Resources for Alzheimer's Disease Franchise
Published: 2024-01-31 (Crawled : 12:30) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -21.02% | O: 0.24% H: 1.74% C: -0.41%
disease alzheimer's

Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
Published: 2024-01-03 (Crawled : 18:00) - biospace.com/
IONS | $40.81 -0.24% -0.25% 5

Health Technology

| -22.81% | O: -0.72% H: 0.55% C: -1.71%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -27.1% | O: 0.21% H: 0.01% C: -1.8%
spinraza first system therapeutics study

Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.25% | O: 3.66% H: 0.0% C: -0.12%
AZNCF | $138.24 -1.36% -4.19% 800

Health Technology

| 3.68% | O: 3.33% H: 0.0% C: -2.93%
NVO | $122.75 -1.43% 0.67% 42K

Health Technology

| 20.34% | O: -0.31% H: 0.39% C: -0.44%
JNJ | News | $145.74 0.67% -0.36% 8.1K

Health Technology

| -5.58% | O: 1.09% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.13% 17K

Health Technology

| 31.25% | O: 0.18% H: 0.5% C: -0.46%
BMY | $48.3 0.96% 0.21% 3.3K

Health Technology

| -5.77% | O: -0.78% H: 5.15% C: 2.81%
ABBV | News | $164.66 0.25% -0.55% 0

Health Technology

| 8.24% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M

Health Technology

| -6.61% | O: 1.03% H: 0.0% C: 0.0%
REGN | $893.99 -0.8% -0.84% 0

Health Technology

| 7.04% | O: 0.52% H: 0.58% C: 0.05%
GILD | News | $66.16 -1.15% -1.16% 1.4K

Health Technology

| -15.24% | O: 0.34% H: 1.02% C: 0.59%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -23.13% | O: 0.57% H: 1.36% C: 1.04%
AZN | $68.36 -0.25% -0.25% 27K

Health Technology

| 2.96% | O: 1.06% H: 0.18% C: -1.06%
AMGN | $262.75 -0.5% -0.49% 320

Health Technology

| -5.15% | O: 0.24% H: 2.03% C: 1.49%
patent report global market

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Published: 2023-12-15 (Crawled : 14:00) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -23.93% | O: 0.31% H: 0.98% C: -3.58%
skyclarys rare first disease chmp positive treat neurodegenerative therapy

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
SAGE | $13.035 3.7% 3.53% 370

Health Technology

| -41.12% | O: 3.04% H: 0.0% C: -3.59%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -23.64% | O: 0.56% H: 1.74% C: -0.18%
depression treatment women

Alzheimer's Disease Therapeutics Market size to grow by USD 5.41 billion from 2023-2028; North America to account for 39% of market growth - Technavio
Published: 2023-12-12 (Crawled : 20:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380

Health Technology

| 28.85% | O: -10.21% H: 0.0% C: 0.0%
GIKLY | $4.58 -0.43% 132.75% 820

Manufacturing

| -36.02% | O: 2.92% H: 0.0% C: 0.0%
NVS | $92.57 -0.55% 0.51% 0

Health Technology

| -5.18% | O: 0.71% H: 0.88% C: 0.85%
ABBV | News | $164.66 0.25% -0.55% 0

Health Technology

| 7.78% | O: -0.17% H: 1.17% C: 0.86%
DNLI | $16.6 -1.31% -1.33% 450

Health Technology

| -10.11% | O: 2.9% H: 8.82% C: 8.56%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -21.64% | O: 0.09% H: 2.58% C: 2.52%
america disease alzheimer's therapeutics growth market

Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million from 2023 to 2028, North America to account for 42% of market growth - Technavio
Published: 2023-12-07 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 2.34% | O: 2.06% H: 0.82% C: 0.82%
ELDN | $1.99 26.75% 21.11% 300K

Manufacturing

| 26.98% | O: -1.59% H: 7.26% C: 2.42%
SNY | News | $45.39 -1.56% -1.58% 4.3M

Health Technology

| -0.46% | O: 1.07% H: 0.0% C: 0.0%
DNLI | $16.6 -1.31% -1.33% 450

Health Technology

| -7.47% | O: -0.21% H: 0.08% C: -1.76%
BCLI | $0.5143 -4.9% -7.51% 0

Health Technology

| 129.73% | O: 0.0% H: 3.56% C: -9.77%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -18.39% | O: -0.61% H: 1.33% C: 0.69%
america sclerosis treatment growth market

Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for CVDs and orphan diseases is the major market trend- Technavio
Published: 2023-12-01 (Crawled : 08:00) - prnewswire.com
ALPMF | $9.17 -4.42% 43.47% 16K

Health Technology

| -18.49% | O: 3.87% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| -2.99% | O: 1.48% H: 0.0% C: 0.0%
ALPMY | $9.47 0.11% -1.11% 10K

Manufacturing

| -23.19% | O: -3.37% H: 4.51% C: 4.51%
NVS | $92.57 -0.55% 0.51% 0

Health Technology

| -4.92% | O: -0.25% H: 0.68% C: 0.48%
ORTX | $16.7 0.0% 370K

Health Technology

| 2.53% | O: -0.09% H: 0.0% C: 0.0%
GBIO | $2.78 -6.71% -7.39% 10

Health Technology

| 163.72% | O: 0.0% H: 38.05% C: 23.01%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -16.63% | O: -0.06% H: 0.35% C: 0.29%
AMGN | $262.75 -0.5% -0.49% 320

Health Technology

| -1.74% | O: 0.12% H: 0.97% C: 0.92%
ADAP | $0.8984 -8.98% -9.86% 48K

Health Technology

| 106.0% | O: -5.76% H: 16.36% C: 15.07%
ABEO | $7.53 -5.04% -5.03% 12

Health Technology

| 52.43% | O: -2.43% H: 0.0% C: 0.0%
research growing therapy market

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.55% 0

Health Technology

| 16.48% | O: -0.28% H: 0.0% C: 0.0%
SMMT A | $3.51 -1.68% -1.71% 2

Health Technology

| 63.76% | O: -0.46% H: 6.68% C: -11.75%
PLSE | $7.36 -1.47% -1.36% 20

Health Technology

| 43.93% | O: 0.39% H: 6.43% C: 1.92%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -21.51% | O: -0.82% H: 0.73% C: -0.4%
ALNY | News | $145.16 -0.11% -0.19% 1

Health Technology

| -13.16% | O: 1.06% H: 2.42% C: 0.76%
therapeutics financial results

Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market growth- Technavio
Published: 2023-11-03 (Crawled : 23:00) - prnewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| Email alert Add to watchlist
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
ALPMF | $9.17 -4.42% 43.47% 16K

Health Technology

| Email alert Add to watchlist
ORTX | $16.7 0.0% 370K

Health Technology

| Email alert Add to watchlist
ABEO | $7.53 -5.04% -5.03% 12

Health Technology

| Email alert Add to watchlist
AMGN | $262.75 -0.5% -0.49% 320

Health Technology

| Email alert Add to watchlist
GBIO | $2.78 -6.71% -7.39% 10

Health Technology

| Email alert Add to watchlist
ADAP | $0.8984 -8.98% -9.86% 48K

Health Technology

| Email alert Add to watchlist
AAPL | News S | $167.04 -0.57% -0.69% 390K

Electronic Technology

| Email alert Add to watchlist
NVS | $92.57 -0.55% 0.51% 0

Health Technology

| Email alert Add to watchlist
ALPMY | $9.47 0.11% -1.11% 10K

Manufacturing

| Email alert Add to watchlist
america therapy market

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
Published: 2023-10-25 (Crawled : 15:00) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -22.59% | O: -0.88% H: 0.34% C: -1.27%
disease alzheimer’s tau promise potential

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
Published: 2023-09-25 (Crawled : 05:00) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -24.27% | O: -0.23% H: 0.0% C: -0.81%
leqembi disease japan approved alzheimer’s treatment

Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for 45% of market growth - Technavio
Published: 2023-09-18 (Crawled : 09:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 0

Health Technology

| 9.19% | O: 2.7% H: 0.0% C: -5.11%
AZNCF | $138.24 -1.36% -4.19% 800

Health Technology

| -2.15% | O: -2.01% H: 1.73% C: -2.99%
NVSEF | $93.6375 6.88% 82K

Health Technology

| 9.62% | O: -0.05% H: 0.0% C: -1.31%
NVS | $92.57 -0.55% 0.51% 0

Health Technology

| -9.31% | O: 0.06% H: 0.09% C: -0.6%
MDT | $79.19 0.14% -0.57% 5.1M

Health Technology

| -3.29% | O: 0.59% H: 1.69% C: 0.67%
GSK | $39.27 -0.83% 0.38% 3.8K

Health Technology

| 5.8% | O: 0.72% H: 0.13% C: -0.93%
BAX | $39.65 0.33% 0.0% 5

Health Technology

| 1.59% | O: -0.13% H: 0.28% C: -0.77%
ABBV | News | $164.66 0.25% -0.55% 0

Health Technology

| 8.2% | O: 0.33% H: 0.0% C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M

Health Technology

| -17.25% | O: -1.29% H: 0.0% C: 0.0%
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -23.41% | O: 0.06% H: 0.44% C: -0.64%
AZN | $68.36 -0.25% -0.25% 27K

Health Technology

| -0.01% | O: -0.76% H: 0.16% C: -1.65%
AMGN | $262.75 -0.5% -0.49% 320

Health Technology

| 1.62% | O: 1.02% H: 0.7% C: -0.09%
america growth market

Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management
Published: 2023-09-06 (Crawled : 18:00) - biospace.com/
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -26.72% | O: 0.07% H: 0.0% C: -1.03%
octave management solution sclerosis care study

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Published: 2023-08-05 (Crawled : 04:20) - globenewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| Email alert Add to watchlist
SAGE | $13.035 3.7% 3.53% 370

Health Technology

| Email alert Add to watchlist
fda approved treatment women response

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-07-07 (Crawled : 00:00) - prnewswire.com
BIIB | $190.52 -0.85% -0.84% 1.3M

Health Technology

| -31.52% | O: 0.21% H: 0.34% C: -3.68%
leqembi fda disease approval treatment alzheimer's grants

← Previous
1
2
3
4
5
6
Next →

for entities : Biogen inc.

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

for entities : Biogen inc. save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

for entities : Biogen inc.

save search